Wednesday, 18 October 2017

Antivirals Market to Record Study Growth by 2024

Global Antivirals Market: Overview
An antiviral is an agent that eliminates a virus or restrains its ability to multiply and hence, prevents it from replicating and reproducing. Antiviral drugs are used in the treatment of lethal viral infections such as HIV, hepatitis B and C viruses, influenza A and B viruses, and herpes viruses. According to WHO, 36.7 million people were living with HIV at the end of 2015.

Request Sample Copy of the Report@ 

Although the development of antivirals has lagged behind that of antibiotics, the report finds that this sector is presented with vast unmet medical needs and substantial profits for drug candidates who invest in the production of new antiviral drugs. As a result, the number of biotechnology companies focusing on R&D activities for advanced antivirals is second only to cancer. According to the report, the global market for antivirals is expected to expand at a moderately healthy CAGR during the forecast period of 2016 to 2024.
Global Antivirals Market: Trends and Opportunities
Some of the primary trends in the global market for antivirals are the development of new mechanisms and research on second-generation molecules, combination therapies, and topical administration routes. Investors proactively pursue research and development of drug candidates for viral diseases that require long-term treatment. They also prefer initiatives that have a predominant patient-base in developed regions of the world and are readily accepted by physicians and drug formularies. Antivirals ideally fit the profile and hence are gaining strong investments. Moreover, the need to improve the quality of life of the patients on the available antiviral regimens is encouraging efforts for the development of second-generation molecules, such as IFN-α.
Several patent expiries are expected during the forecast period of the report, such as Sustiva, Tamiflu, Tenofovir, Combivir, Telbivudine, and Relenza. The report expects the patent expiries of these blockbuster drugs will trigger the development of generic therapeutics in the global antivirals market and make it more competitive. Pipeline drugs such as Rilpivirine, Elvitegravir, Vicriviroc, and Rapiacta are expected to positively impact the market upon arrival.
Some of the other factors driving the global market for antivirals are the increase in healthcare infrastructure spending not only in developed countries but also among emerging economies, the rising prevalence of life-threatening viral diseases, and an increase in public awareness. Conversely, the high cost of R&D and stringent government policies are expected to hinder the growth of the global market for antivirals.
On the basis of products, the global market can be segmented into antivirals for hepatitis-C, hepatitis-B, HIV, herpes, influenza, and others. The market can also be segmented on the basis of enzyme specific actions, such as DNA polymerase inhibitors, reverse transcriptase inhibitors, NS3 Protease inhibitors, and others.
Global Antivirals Market: Region-wise Outlook
Geographically, the global market for antivirals can be segmented into North America, Europe, Asia Pacific and Rest of the World. The report points out that the U.S. is the most prominent market for antiviral drugs, dominating the North American region with a strong healthcare infrastructure and the presence of several prominent players. The U.K. leads in the European market while Japan is a significant market in Asia Pacific. Several countries in Asia Pacific and Africa are expected to grow at a robust rate during the forecast period of 2016 to 2024.

Request TOC of the Report@ 

Some of the key players currently operational in the global market for antivirals are Abbott Laboratories, GlaxoSmithKline, plc, BoehringerIngelheim Corporation, AstraZeneca AB, Novartis International AG, Merck and Co. Inc., and Johnson & Johnson.
Major regions analyzed under this research report are:
  • Europe
  • North America
  • Asia Pacific
  • Rest of the World
This report gives you access to decisive data such as:

  • Market growth drivers
  • Factors limiting market growth
  • Current market trends
  • Market structure
  • Market projections for the coming years

Tuesday, 17 October 2017

Epinephrine Market trends estimates high demand by 2019

Epinephrine or adrenaline is a hormone secreted by adrenal glands in the blood stream. It is one of the two common hormones (the other being glucagon) that is responsible for glycogen breakdown. Secretion of epinephrine is characterized by the presence of extreme emotions such as anxiety or anger thereby resulting in elevated levels of blood pressure along with increased muscle strength and high sugar metabolism. Under strenuous conditions signals are transmitted to brain and brain in turn sends nerve impulses to the adrenal glands in the kidneys and result in the release or secretion of epinephrine. The presence of this hormone is essential for the body to maintain cardiovascular homeostasis as epinephrine can divert blood to tissues under stress. Epinephrine is used as a vasoconstrictor in shock, as a stimulant during cardiac arrest and as an antispasmodic and bronchodilator in bronchial asthma.
 
 
 
During cardiac arrest, there is a need for maximum amount of blood flow in the coronary artery and this is facilitated when epinephrine is injected into an intravenous solution. Epinephrine has effects on various parts of the body such as liver, skin, heart and lungs. For instance, in lungs epinephrine causes the relaxation of smooth muscles of lungs. Patients suffering from asthma have constricted lung passages that are prone to inflammation and swelling. This swelling result in coughing, wheezing, shortness of breath and due to inhalation of epinephrine in small doses causes the widening of the bronchial tubes thereby allowing the air to pass through and provides short term relief. 
 
Epinephrine injections are commonly used against life threatening allergic reactions caused by medications, insect bites and stings. Epinephrine injections are available as prefilled automatic injection device with the hormone in the liquid form. Epinephrine is a class of medications called as alpha and beta adrenergic agonists and these medications work by tightening the blood vessels and by relaxing the muscles in the airways. The direction for preparing and use of the injectors is dependent on different brands available in the market. This injection is usually administered on the thighs and effects of this medication are fast and quick but not long lasting. Epinephrine has both mild and serious side effects such as high blood pressure, severe headache, blurred vision, chest pain, uneven heartbeats, dizziness, nausea and vomiting. 
 
The market for epinephrine auto-injector market exhibits tremendous growth potential owing to several technological advances towards development of innovative epinephrine injectors. Epinephrine auto injectors market can be analyzed on the basis of the product penetration and availability across the four major geographical regions namely North America, Europe, Asia-Pacific and RoW. Adrenaclick, EpiPen Auto-Injector, Adrenalin Chloride Solution and EpiPen Jr. Auto-Injector, epinephrine lidocaine hydrochloride are some of the brands of epinephrine autoinjectors. 
 
Some of the major factors favoring the growth of this market are increasing number of patient population susceptible to several allergic reactions along with increased focus of the market players towards development of chlorofluorocarbon (CFC) free epinephrine auto-injectors. This is majorly due to the ban on the use of CFC as a propellant inhaler by the U.S. Government. 
 
In addition, continuous product modifications, increased need and demand of automatic injection devices further propel the growth and development of epinephrine auto injectors market. On the contrary, the side effects caused by epinephrine medications pose a challenge to the growth of the market. Owing to the potential side effects (dizziness, shortness of breath and severe headache) of epinephrine therapy, doctors recommend or prescribe other alternative pharmacotherapy and immunotherapy against allergic reactions. The key market players operating in this market are Abbott Laboratories, Lincoln Medical, Ltd., Mylan, Inc., Sanofi SA, Amedra Pharmaceuticals LLC and ALK Abello A/S. 
 
 
 
This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include 
  • North America 
  • Asia Pacific 
  • Europe
  • Rest of the World  
This report provides comprehensive analysis of 

  • Market growth drivers 
  • Factors limiting market growth
  • Current market trends 
  • Market structure
  • Market projections for upcoming years

Epilepsy Therapeutics Market to Record Study Growth by 2024

Global Epilepsy Therapeutics Market: Overview
Epilepsy refers to a chronic disorder in which seizures reoccur unprovoked. The cases of epilepsy exhibit more than one type of seizure and may have other symptoms of neurological problems too. Sometimes family background, clinical history, and EEG testing reflect similar symptoms among a group of people, which is defined as a specific epilepsy syndrome. Though the symptoms of seizure can affect any part of the body, human brain is the source of epilepsy, and a vast population suffer from this disorder across the world. According to the World Health Organization (WHO), nearly 50 million people have epilepsy globally, which makes it one of the most common neurological diseases worldwide. The demand in the global epilepsy therapeutics market is sustained by this large population, which is projected for a healthy growth rate during the forecast period of 2016 to 2024.

Request Sample Copy of the Report@
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2448

This report on global market for epilepsy therapeutics market is a comprehensive analysis of all the factors that are expected to influence the growth rate and presents a figurative estimation of the opportunities. The report also highlights some of the key trends in the market, which must be utilized by the current players and gain advantage over their competitors. The present a clear picture of the competitive landscape, the report also profiles some of the leading players and gives-out their market share, product portfolio, and strategic developments.
The global epilepsy therapeutics market is categorized into two major categories, namely first generation anti-epileptic drugs (AEDs) and second generation anti-epileptic drugs. Second generation AEDs consist of medicines with different mechanism of action than the first generation drugs. While first generation AEDs such as valproate, carbamazepine, oxycarbazepine, and phenytoin currently dominate the demand in the global epilepsy therapeutics market, second generation AEDs such as zonisamide, levetiracetam, and lacosamide are steadily overtaking the market, gaining favor due to its improved efficacy and tolerability.
Global Epilepsy Therapeutics Market: Trends and Opportunities
Besides an existing large patient base and the increasing prevalence of neurological disorders, the report observes that timely therapeutics leads to a positive response approximately in 70% of the case. This factor entices physicians to recommend the latest therapeutics and patients actively indulge into the process. The technological advancements in epilepsy therapeutics is another factor favoring the growth rate. Additionally, the awareness pertaining to the availability of latest diagnostics and treatment methods among the consumers is on the increasing, which will further increment the demand during the forecast period. However, the WHO report observes that nearly 80% of the people with epilepsy live in low-and middle-income countries with poor medical facilities, which is the primary factors expected to hinder the growth rate. The prescribing pattern of drugs that give preference to first generation AEDs over second generation AEDs is also expected to act as a restraint over the market. However, ongoing research and development in the healthcare literacy rate will open new growth avenues for the market players in the near future. In the US, three new anti-epileptic drugs have been approved since 2012, which are Aptiom, Trobalt, and Fycompa, while brivaracetam is expected also to be launched soon.
Global Epilepsy Therapeutics Market: Region-wise Outlook
Currently, North America serves the maximum demand for epilepsy therapeutics, primarily driven by the country-wide market of the U.S. and Canada, which have robust healthcare infrastructure. However, several emerging economies in the region of Asia Pacific are actively improving their medical facilities and disposable income is increasing in these parts too, which will reflect on extended demand from this regional market.

Request TOC of the Report@
 https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=2448

Companies mentioned in the research report
Pfizer, Inc., Novartis AG, Abbott Laboratories, GlaxoSmithKline plc, Johnson & Johnson, Cephalon, Inc., Sunovion Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., Sanofi S.A. and Shire.
Major regions analyzed under this research report are:
  • Europe
  • North America
  • Asia Pacific
  • Rest of the World
This report gives you access to decisive data such as:

  • Market growth drivers
  • Factors limiting market growth
  • Current market trends
  • Market structure
  • Market projections for the coming years

Aurora Kinase Inhibitors Market Intelligence with Competitive Landscape 2023

Global Aurora Kinase Inhibitors Market: Overview
As the importance of aurora kinases was recognized due to their significance in human biology and cancer therapy, the demand for aurora kinase inhibitors has been surmounting of late. Aurora kinases are a type of enzymes that play a significant role in cell proliferation. In the mitosis process, these enzymes undertake the responsibility of breaking down the genetic material of the parent cells via the control of chromatid segregation.

Request Sample Copy of the Report@
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4679

Based on type of aurora kinase enzymes, A, B, and C can be the key segments of the global market for aurora kinase inhibitors. While aurora A and B lead to tumerogenesis, aurora C is associated with spermatogenesis process. Although they are not associated with a certain type of cancer, some instances of cancer exhibit over-expression of a particular type of aurora kinases. Aurora B was found to be related to thyroid, breast, and colon, whereas aurora A was found to be associated with prostate, pancreatic, ovarian, cervical, lung, breast, and brain.
The report offers key information pertaining to the leading growth drivers, deterrents, and market trends. The key opportunities proffered by the different regional segments have been analyzed in detail, alongside relevant market data, charts, and figures. Efficient analytic tools such as the Porter’s Five Force analysis and SWOT analysis have been adopted by the study to produce accurate evaluations. The major players transacting in the global market for aurora kinase inhibitors are also assessed with regards to their market shares, product portfolios, and business strategies.
Global Aurora Kinase Inhibitors Market: Trends & Opportunities/Drivers and Restraints
The rising incidence of cancer on a worldwide scale has been fuelling the demand for aurora kinase inhibitors recently. Cancer has been found to be one of the foremost factors increasing mortality rates over the globe. According to the World Health Organization (WHO), by the end of 2025 the number of cancer patients will reach nearly 19.3 million, which was 14.1 million during 2012. The study also reveals that more than 8.2 million people die from cancer, of which almost 522,000 are women diagnosed with breast cancer. While the mortality rates are higher in the developing regions of the world, the frequency of cancer is higher in developed countries.
The progress of the global market for aurora kinase inhibitors can receive a blow due to the exorbitant costs required in the development of these inhibitors. Small manufacturers might not possess enough capital to invest massively in the creation of advanced aurora kinase inhibitors. Moreover, lack of awareness among the developing economies can also restrict the expansion of the market. However, the adoption of several biological therapies in the domain of oncology will create opportunities for further expansion of the market.
Global Aurora Kinase Inhibitors Market: Regional Outlook
By geography, the global market for aurora kinase inhibitors can be segmented into Latin America, Middle East and Africa, Europe, Asia Pacific, and North America. The countries in North America witnessed greater growth when compared with other regions. As a result, North America accounted for the greatest portion of the global revenue. The continuous upgrading of the healthcare sector has been propelling the market for aurora kinase inhibitors in North America.
High growth rate of geriatric population and heightening incidence of cancer rates in Asia Pacific have been responsible for the burgeoning demand for aurora kinase inhibitors in the region. India, China, South Korea, Japan, Malaysia, and Indonesia are likely to contribute substantially to the growth of the market for aurora kinase inhibitors in Asia Pacific over the next few years.

Request TOC of the Report@
https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=4679

Companies mentioned in the research report
Cyclacel Pharmaceuticals, Pfizer, Eli Lilly, GlaxoSmithKline, Millennium Pharmaceuticals, Merck, Bristol Myers Squibb, Celgene, Roche, Sanofi, and Novartis are some leading companies operating in the global market for aurora kinase inhibitors.
Major regions analyzed under this research report are:
  • Europe
  • North America
  • Asia Pacific
  • Rest of the World
This report gives you access to decisive data such as:

  • Market growth drivers
  • Factors limiting market growth
  • Current market trends
  • Market structure
  • Market projections for the coming years

EpCAM Antagonists Market Intelligence with Competitive Landscape 2023

Global EpCAM Antagonists Market: Overview
Epithelial cell adhesion molecule (EpCAM), is a cell surface protein or antigen, which is considered an highly expressed element in most of the key cancer types, including prostate, breast, colon, lung, gastric, ovarian, and pancreatic cancer. As a result, EpCAM antagonists are considered as well-established as an ideal therapeutic target and market for cancer of epithelial origin. The growing focus of leading players on research and development activities and technological advancements in the healthcare sector are projected to encourage the growth of the global EpCAM antagonists market throughout the forecast period.

Request Sample Copy of the Report@
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4678

The research study offers a detailed analysis of the global EpCAM antagonists market, presenting insights into the important factors that are projected to impact the growth of the overall market in the near future. In addition, the driving factors, restraints, and the promising opportunities in the global EpCAM antagonists market have been highlighted in order to offer a strong understanding of the overall market. The product segmentation, innovations and developments, latest trends, major applications, key regional segments, and the competitive landscape of the global EpCAM antagonists market have been discussed in the research report.
Global EpCAM Antagonists Market: Drivers and Barriers
The tremendously rising prevalence of different types of cancer across the globe is one of the key factors estimated to fuel the growth of the global EpCAM antagonists market throughout the forecast period. In addition, the rising government initiatives and spending on research and development activities for cancer treatment are expected to accelerate the growth of the overall market in the next few years. Furthermore, the constant development in the field of recombinant DNA technology is projected to offer promising opportunities for the key players operating in the global market for EpCAM antagonists.
However, the lack of awareness regarding the availability of advanced therapeutics, especially in developing economies and the high cost of overall cancer treatments are some of the key factors likely to restrict the growth of the global EpCAM antagonists market in the coming few years.
Global EpCAM Antagonists Market: Regional Outlook
The global market for EpCAM antagonists can be classified in terms of geography to offer an in-depth analysis. The key regional segments include Asia Pacific, Europe, North America, and the Rest of the World. Among these, North America is projected to lead the overall market and account for a large share throughout the forecast period. The presence of a large number of leading players operating in this region is one of the major factors estimated to supplement the growth of the EpCAM antagonists market in the next few years.
Furthermore, the rising number of cancer cases in this region is another factor encouraging the growth of the market in the next few years. On the other hand, Asia Pacific is projected to witness significant growth in the coming years. 
Companies Mentioned in the Research Report
Some of the key players operating in the EpCAM antagonists market across the globe are Johnson and Johnson, Amgen, Inc., Fresenius Biotech, The University of Hong Kong and American Association for Cancer Research, and Trion Pharma GmbH. The increasing number of players entering the global market and focusing on research and development activities are some of the factors estimated to accelerate the growth of the global EpCAM antagonists market throughout the forecast period.

Request TOC of the Report@
https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=4678

Furthermore, to offer a clear picture of the competitive landscape of the global  EpCAM antagonists market, the research study has provided detailed analysis of the key players in the market. The company profiles, business policies, financial overview, SWOT analysis, recent developments, mergers and acquisitions, and product portfolio have been discussed at length in the scope of the research study.
The global EpCAM antagonists market has been segmented as: 
Global EpCAM Antagonists Market, by Geography 
  • North America
  • Europe
  • Asia Pacific
  • Rest of the World 
This report gives you access to decisive data such as: 

  • Market growth drivers
  • Factors limiting market growth
  • Current market trends
  • Market structure
  • Market projections for the coming years 

Super Resolution Microscopes Market to Record Study Growth by 2024

Global Super Resolution Microscopes Market: Overview
Traditional microscopes work by magnifying the light passing through a sample using lenses. This produces a magnified picture. However, these microscopes have focusses limited to the diffraction of light that happens mostly beyond a selected magnification. Enter super resolution microscopes (SRMs). They are highly specialized modified light microscopes that overcome the diffraction limit of light to provide high resolution image of an object. This is brought about either by facilitating the reconstruction of an image under scan by nanometer scale scanning devices, or by true super resolution methods carried out via super lens, better axial resolution by 4Pi microscopy method, or by making use of pre diffracted light which is near field optics.

Request Sample Copy of the Report@
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4673

Global Super Resolution Microscopes Market: Trends and Opportunities
The global market for super resolution microscopes will expand at a cracking pace in the years to come on account of the growing government support and corporate funding for microscopy, technological advancements and growing focus on nanotechnology. 
Depending upon the technology leveraged, the global market for super resolution microscopes can be segmented into stochastic function resolution technique, deterministic functional resolution technique, true super resolution technique, and combination resolution techniques. True super resolution techniques can be further segmented into structured illumination microscopes, near field scanning optical microscopes, 4Pi microscopes, etc. Similarly, deterministic techniques can be further sub-divided into GSD (Ground state depletion) microscopy, STED (Stimulation emission depletion) microscopy, and SSIM (Saturated structured illumination) microscopy. Stochastic techniques are also be classified further.
Application-wise, the global market for super resolution microscopes can be classified into nanotechnology industry, geo-material research, material sciences, and semiconductor manufacturing and research laboratories. The life sciences segment, among them, accounts for maximum market share. Material sciences and nanotechnology are other key segments. This is because, the design and applicability of super resolution microscopes manufactured particularly for these industries are highly modified for a particular use in their respective fields.
Global Super Resolution Microscopes Market: Regional Outlook
From a geographic standpoint, North America and Asia Pacific are the main markets for super resolution microscopes. Powered primarily by Japan, China, and Australia, the demand in the Asia Pacific is predicted to expand substantially in the foreseeable future. South Asia and South East Asia have been contributing significantly to the demand owing to their applications in the field life sciences and semi-conductor. The market in Asia Pacific is also seeing a lot of action on account of the concentration of numerous industrial microscope manufacturers in the region.
North America is another major market on account of the robust life science and semi conductors industry in the region. Europe too accounts for a substantial share because of the presence of a large super resolution microscope manufacturing industry in the region replete with renowned names producing high quality products. There are, however, a few factors countering the growth in the market in Europe and North America. They are myriad restrictions on genome engineering, reduced funding for life science research, and moving of semi-conductor manufacturing to the Asian countries. 

Request TOC of the Report@
https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=4673

Companies Mentioned in the Report
To assess the competition prevailing in the global market for super resolution microscopes, the report profiles companies such as Hitachi High Tech Corporation., JEOL Ltd, Carl Zeiss AG, Olympus Inc, GE LifeSciences, Nikon Corporation, FEI Company, Leica Microsystems, Bruker Corporation, etc.
This report gives you access to decisive data such as: 

  • Market growth drivers
  • Factors limiting market growth
  • Current market trends
  • Market structure
  • Market projections for the coming years 

Monday, 16 October 2017

Assisted Reproduction Technology Devices Market show exponential growth by 2024

Global Assisted Reproduction Technology Devices Market: Snapshot
Assisted reproduction technology (ART) devices have been designed and developed to solve issues pertaining to fertility. Ever since the initial introduction of IVF (in-vitro fertilization) in 1978, technique to resolve pregnancy related issues have come a long way. The advent of assisted reproductive technology offer solutions such as in-vitro fertilization (IVF), gamete intrafallopian transfer (GIFT), intracytoplasmic sperm injection (ICSI), zygote intrafallopian transfer (ZIFT), intrauterine insemination (IUI), and surrogacy. The Centers for Disease Control and Prevention (CDC) states that 208,604 ART cycles were conducted at 458 clinics in the U.S., of which 57,323 were live births and 70,354 were live born infants in 2014. Though the usage of ART is not significant, its demand has still soared in the recent past.

Request Sample Copy of the Report@
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=14330

The research report by Transparency Market Research provides a comprehensive outlook of the global assisted reproduction technology devices market. The publication is aimed at providing a detailed analysis of the segments in the market, the competitive landscape, financial outlook of the companies operating in the market, and the supply chain analysis.
Global Assisted Reproduction Technology Devices Market: Drivers and Trends
The global assisted reproduction technology devices market is expected to witness a significant boost in the coming years due to the growing support by governments for research and development. The rise in funding for developing efficient and safe assisted reproduction technology devices is expected to make a positive impact on the global market.
The high prevalence of male and female infertility due to poor lifestyle choices, deferred pregnancies, and health conditions have collectively boosted the demand for assisted reproduction technology devices. Infertility in males is observed due to poor sperm count, blocked sperm ducts, and poor sperm movement. On the other hand, female infertility is usually a result of dysfunctional fallopian tubes along with issues related to cervix or uterus.
The growth of medical tourism and the possibility of surrogacy in emerging economies has been crucial to the growth of this market in recent years. The high cost of using these technologies and devices in developed countries has dissuaded several patients and made them migrate to developing countries, where seeking medical treatment is relatively cheaper. 
Global Assisted Reproduction Technology Devices Market: Regional Outlook
The global assisted reproduction technology devices market is segmented into Europe, North America, Asia Pacific, and Rest of the World. Of these, North America is expected to lead the global market in the coming years. The high rate of awareness amongst people about assisted reproduction technology devices market is expected to drive the regional market. Furthermore, incredible governmental support to the overall market in North America for in-vitro fertilization and high infertility rates are projected to boost the market’s growth.
Europe also expected to steady growth in the overall assisted reproduction technology devices market in the coming years. The rising rate of medical tourism and acceptance of IVF are expected to propel the regional market in the coming years. Asia Pacific is also projected to emerge as a significant market for the assisted reproduction technology devices due to the emergence of medical tourism industry. The rising disposable incomes, late pregnancies, and rising women employment are expected to fuel the growth of this regional market in the near future. 

Request TOC of the Report@
https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=14330

Key Players Mentioned in this Report are:

Some of the key players operating in the global assisted reproduction technology devices market are Microm UK Limited, Irvine Scientific, Parallabs, Cryolab Ltd., European Sperm Bank Cosmos Biomedical Limited, and Origio.